BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
14 July 2022 - 6:01AM
Business Wire
BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and
Nasdaq: BLU), announced today the filing of a preliminary
prospectus supplement (the “Supplement”) to its amended and
restated short form base shelf prospectus dated December 14, 2021,
amending and restating the short form base shelf prospectus dated
December 23, 2020 (the “A&R Base Prospectus”) in connection
with a proposed public offering of its common shares (the
“Offering”). The Supplement was filed with each of the securities
regulatory authorities in the provinces of Canada. The Supplement
and accompanying A&R Base Prospectus were also filed with the
U.S. Securities and Exchange Commission (the “SEC”) as part of a
registration statement on Form F-10, as it may be amended from time
to time, in accordance with the Multijurisdictional Disclosure
System established between Canada and the United States. The
Company intends to use the net proceeds of the Offering primarily
to fund BLU-5937 research and development activities, working
capital needs and other general corporate purposes, as set out in
the Supplement.
The Company also expects to grant to the underwriters a 30-day
option to purchase up to an additional 15% of the number of common
shares offered in the Offering. The Offering is expected to be
priced in the context of the market, with the final terms of the
Offering to be determined at the time of pricing. There can be no
assurance as to whether or when the Offering may be completed, or
as to the actual size or terms of the Offering. The closing of the
Offering will be subject to customary closing conditions including
approval from the Toronto Stock Exchange (the “TSX”). For the
purposes of the TSX approval, the Company intends to rely on the
exemption set forth in Section 602.1 of the TSX Company Manual,
which provides that the TSX will not apply its standards to certain
transactions involving eligible interlisted issuers on a recognized
exchange, such as the Nasdaq Global Market (“Nasdaq”).
Jefferies, Evercore ISI and RBC Capital Markets are acting as
joint book-running managers.
The Supplement and the accompanying A&R Base Prospectus
contain important detailed information about the Offering. The
Supplement and the accompanying A&R Base Prospectus can be
found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies
of the Supplement and accompanying A&R Base Prospectus may also
be obtained from the Company, by telephone at 450-680-4500 or by
email at info@bellushealth.com or you may request them from, in the
United States, Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, New York, NY 10022, by
telephone at 877-821-7388 or by email at
prospectus_department@jefferies.com, or Evercore Group L.L.C.,
Attention: Equity Capital Markets , 55 East 52nd Street, 35th
Floor, New York, NY 10055, by telephone at 888-474-0200 or by email
at ecm.prospectus@evercore.com, or RBC Capital Markets, LLC,
Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New
York, NY 10281, by telephone at 877-822-4089 or by email at
equityprospectus@rbccm.com or, in Canada, Jefferies Securities,
Inc., Attention: General Counsel, 161 Bay Street, Suite 2600,
Toronto, ON M5J 2S1 by email at
prospectus_department@jefferies.com, or RBC Dominion Securities
Inc., Attention: Distribution Centre, 180 Wellington Street West,
8th Floor, Toronto, ON M5J 0C2, by telephone at 1-416-842-5349 or
by email at Distribution.RBCDS@rbccm.com. Prospective
investors should read the Supplement and accompanying A&R Base
Prospectus and the other documents the Company has filed before
making an investment decision.
No regulatory authority has either approved or disapproved the
contents of this news release. This news release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any province,
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under
the securities laws of any such province, state or
jurisdiction.
About BELLUS Health
BELLUS Health Inc. is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of refractory
chronic cough (“RCC”) and other hypersensitization-related
disorders. The Company's product candidate, BLU-5937, is being
developed for the treatment of adults with RCC.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute "forward-looking statements" within the
meaning of Canadian securities legislation and regulations, the
U.S. Private Securities Litigation Reform Act of 1995, as amended,
and other applicable securities laws. Such statements, based as
they are on the current expectations of management, inherently
involve numerous important risks, uncertainties and assumptions,
known and unknown. In this news release, such forward-looking
statements include, but are not limited to, statements regarding
the Offering, the granting of the option to purchase additional
shares and the anticipated use of proceeds from the Offering.
Completion of the Offering is subject to numerous factors, many of
which are beyond BELLUS Heath’s control, including but not limited
to, market conditions, the failure of the parties to satisfy
certain closing conditions and other important factors disclosed
previously and from time to time in BELLUS Health’s filings with
the securities regulatory authorities in each of the provinces of
Canada and the SEC. Actual future events may differ from the
anticipated events expressed in such forward-looking statements.
BELLUS Health believes that expectations represented by
forward-looking statements are reasonable, yet there can be no
assurance that such expectations will prove to be correct. The
reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These
forward-looking statements speak only as of the date made, and
BELLUS Health is under no obligation and disavows any intention to
update publicly or revise such statements as a result of any new
information, future event, circumstances or otherwise, unless
required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220713005846/en/
Investors: Ramzi Benamar Chief Financial Officer
rbenamar@bellushealth.com Media: Julia Deutsch Solebury
Trout jdeutsch@soleburytrout.com
BELLUS Health (NASDAQ:BLU)
Historical Stock Chart
From Apr 2024 to May 2024
BELLUS Health (NASDAQ:BLU)
Historical Stock Chart
From May 2023 to May 2024